Clin Chem 2018 ; 64: These small differences are likely to have little clinical impact. Lipoprotein a concentrations, rosuvastatin therapy, and residual vascular risk: Clinical- and cost-effectiveness of LDL particle-guided statin therapy: There are 2 isoforms of apoB: Sahlgrenska University Hospital, Gothenburg, Sweden;.
This discordance points to substantial residual risk in many statin-treated patients and the opportunity for further benefit of LDL-lowering therapy that is lost if apoB or LDLP is not measured.
Biomarker development targeting unmet clinical needs. Can J Cardiol 2016 ; 32: Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study IRAS.
Therefore, standardization of NMR spectral analysis is urgently needed, as well as harmonization to a unique reference material to allow comparability of NMR data with other subfractionation techniques 72.
Nutr Metab Cardiovasc Dis 2012 ; 22: They are distinguished from other lipids because of a tendency to accumulate in blood vessels and block circulation, causing cardiovascular disease.
Mora, Amgen, Pfizer, Lilly; G. Atherosclerosis 2009 ; 205: Share This Article: Ann Intern Med 2009 ; 150: Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: After adjustment for clinical risk factors including metabolic syndrome, these risks attenuated to 1. Arterioscler Thromb Vasc Biol 2007 ; 27: